Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of acute rhinosinusitis~* characterized by a major symptom score (MSS) ≥ 8 and ≤ 12 points (minimum 0, maximum 15 points)~* individual score for facial pain/pressure ≥ 1 (mild) and ≤ 2 (moderate)~* confirmed by ultrasonography of paranasal sinuses~* with presence of symptoms ≤ 3 days prior to inclusion~Exclusion Criteria:~* Chronic rhinosinusitis~* Polyposis nasi~* Anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation/airflow~* Acute symptoms of a known allergic rhinitis~* Patients with asthma who have a history of exacerbations within 30 days prior to study inclusion~* Signs or symptoms of fulminant bacterial sinusitis~* Odontogenic sinusitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BNO 1016 (Type: EXPERIMENTAL): sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
- Placebo (Type: PLACEBO_COMPARATOR): sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).